NGeneBio Co., Ltd.
Financials
Valuation Metrics
NGeneBio Co., Ltd.'s Market Cap is ₩120B. At end of 2025 it was ₩320B. Ranked #2396 of 2,421 in KR market (top 99%), #1618 of 1,640 on KOSDAQ (top 99%), #229 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 12.02B KRW | KR#2,396/2,421 Sec#229/231 |
| Revenue | 41.76B KRW | KR#1,896/2,421 Sec#134/231 |
| Net Income | -5.31B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 70.62B KRW | KR#2,006/2,421 Sec#165/231 |
| Net Assets | 18.69B KRW | KR#2,307/2,421 Sec#216/231 |
| Employees | 96 | KR#1,670/2,421 Sec#130/231 |
| Value | ||
| P/B | 0.64x | KR#1,043/2,421 Sec#56/231 |
| P/S | 0.29x | KR#568/2,421 Sec#14/231 |
| FCF Yield | -71.05% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -28.39% | KR#2,171/2,421 Sec#172/231 |
| ROA | -7.51% | KR#2,039/2,421 Sec#150/231 |
| Op. Margin | -13.14% | KR#2,043/2,421 Sec#137/231 |
| Revenue Growth | 525.91% | KR#7/2,421 Sec#4/231 |
| Financial Health | ||
| Debt Ratio | 277.94% | KR#2,240/2,421 Sec#224/231 |
| Total Debt | 51.40B KRW | KR#999/2,421 Sec#69/231 |
| FCF | -8.54B KRW | KR#1,659/2,421 Sec#140/231 |
| Cash | 3.00B KRW | KR#2,161/2,421 Sec#203/231 |
| Current Ratio | 0.45x | KR#2,163/2,421 Sec#211/231 |
| Performance | ||
| 1Y Return | -69.55% | KR#2,295/2,421 Sec#218/231 |
| 1M Return | -27.30% | KR#2,345/2,421 Sec#219/231 |
| From 52W High | -80.18% | KR#2,343/2,421 Sec#218/231 |
| 1Y MDD | -80.50% | KR#2,303/2,421 Sec#209/231 |
| Trading | ||
| Volume | 373,625 shares | KR#304/2,421 Sec#18/231 |
| Trading Value | 513.8M KRW | KR#915/2,421 Sec#92/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | -594 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,091 KRW | KR#2,052/2,421 Sec#171/231 |
Company Info
Established in 2015, NGENBIO is a specialized NGS-based precision diagnostics company. It was listed on the KOSDAQ market in 2020 and expanded its pharmaceutical distribution business through an acquisition in 2025. The company provides gene extraction panels and data analysis software for conditions like breast cancer and blood cancer, and operates toxicology and molecular diagnostics services. NGENBIO supplies products to over 25 major medical institutions in Korea, expands overseas exports, and is leading the precision medicine market. NGENBIO is headquartered in Guro-gu, Seoul.